Atherosclerosis and cardiovascular disease in systemic lupus erythematosus: effects of in vivo statin treatment

Ruiz-Limón, P.; Barbarroja, Nuria; Pérez-Sánchez, C.; Aguirre, María Ángeles; Bertolaccini, Maria Laura; Khamashta, Munther A.; Rodríguez‐Ariza, Antonio; Almadén, Yolanda; Seguí, Pedro; Khraiwesh, Husam; González‐Reyes, José A.; Villalba, José M.; Collantes-Estévez, Eduardo; Cuadrado, María J.; López‐Pedrera, Chary

doi:10.1136/annrheumdis-2013-204351

Cited by 51 publications

(46 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Лечение пациентов с СКВ флувастатином в течение 1 мес уменьшало индекс активности SLEDAI, уровень ли-пидов, окислительный стресс и сосудистое воспаление [37]. Терапия статинами в исследовании LUMINA (LXXVI) привела к существенному уменьшению индекса активности SLAM-R и значительному клиническому улучшению у пациентов с СКВ [89].…”

Section: о б з о р ыunclassified

“…Имеющиеся данные показали, что применение флувастатина у больных СКВ, по-видимо-му, подавляет окислительно-воспалительные механизмы, вовлеченные в развитие атерогенеза [37].…”

Section: о б з о р ыunclassified

“…В свою оче-редь моноциты при СКВ показали измененный митохон-дриальный мембранный потенциал и повышенный окси-дативный стресс. Проведенный анализ подтвердил выра-женные ассоциации между активацией аутоиммунитета, оксидативным стрессом, воспалением и увеличением ри-ска атеротромбоза при СКВ [37].…”

unclassified

See 2 more Smart Citations

Cardiovascular Events in Systemic Lupus Erythematosus: Mechanisms for the Accelerated Development of Atherosclerosis, Diagnosis, Correction Capabilities

Аршинов¹,

Левшин²,

Maslova³

2017

rsp

View full text Add to dashboard Cite

Section: о б з о р ыunclassified

unclassified

See 1 more Smart Citation

Cardiovascular Events in Systemic Lupus Erythematosus: Mechanisms for the Accelerated Development of Atherosclerosis, Diagnosis, Correction Capabilities

Аршинов¹,

Левшин²,

Maslova³

2017

rsp

View full text Add to dashboard Cite

“…SLE monocytes are more prone to oxidative damage (63)* and there is evidence for increases in macrophage proinflammatory subsets M1 and M2b, and decreases in the anti-inflammatory M2a and M2c populations in SLE, which may contribute to inflammation. (64) IFNs drive macrophages to engulf lipids,(48) and enhanced monocyte migration to plaque site increases foam cell production.…”

Section: Pathogenesis Of Premature Atherosclerosis In Slementioning

confidence: 99%

“…(86) Fluvastatin had anti-inflammatory effects on SLE macrophages, lowering ROS production. (63)* A recent study suggested that statin therapy in Taiwanese SLE patients with hyperlipidemia may reduce the risk of mortality, CVD and end-stage renal disease. (94)** As we learn more about the shared pathogenesis of these inflammatory conditions, perhaps specific statin and patient selection will yield greater improvement in CV risk for SLE patients.…”

Section: Pathogenesis Of Premature Atherosclerosis In Slementioning

confidence: 99%

Update on cardiovascular disease in lupus

Lewandowski

Kaplan

2016

Current Opinion in Rheumatology

View full text Add to dashboard Cite

Purpose of Review Atherosclerotic cardiovascular disease confers significant morbidity and mortality in patients with systemic lupus erythematosus (SLE) and cannot be fully explained by traditional cardiovascular risk factors. Recent immunologic discoveries have outlined putative pathways in SLE that may also accelerate the development of atherosclerosis. Recent findings Aberrant innate and adaptive immune responses implicated in lupus pathogenesis may also contribute to the development of accelerated atherosclerosis in these patients. Defective apoptosis, abnormal lipoprotein function, autoantibodies, aberrant neutrophil responses and a dysregulated type I interferon pathway likely contribute to endothelial dysfunction. SLE macrophages have an inflammatory phenotype that may drive progression of plaque. Summary Recent discoveries have placed increase emphasis on the immunology of atherosclerotic cardiovascular disease. Understanding the factors that drive the increase risk for CVD in SLE patients may provide selective therapeutic targets for reducing inflammation and improving outcomes in atherosclerosis.

show abstract

Cholesterol metabolism: physiological regulation and diseases

Guo,

Chen,

Zhang

et al. 2024

MedComm

View full text Add to dashboard Cite

Cholesterol homeostasis is crucial for cellular and systemic function. The disorder of cholesterol metabolism not only accelerates the onset of cardiovascular disease (CVD) but is also the fundamental cause of other ailments. The regulation of cholesterol metabolism in the human is an extremely complex process. Due to the dynamic balance between cholesterol synthesis, intake, efflux and storage, cholesterol metabolism generally remains secure. Disruption of any of these links is likely to have adverse effects on the body. At present, increasing evidence suggests that abnormal cholesterol metabolism is closely related to various systemic diseases. However, the exact mechanism by which cholesterol metabolism contributes to disease pathogenesis remains unclear, and there are still unknown factors. In this review, we outline the metabolic process of cholesterol in the human body, especially reverse cholesterol transport (RCT). Then, we discuss separately the impact of abnormal cholesterol metabolism on common diseases and potential therapeutic targets for each disease, including CVD, tumors, neurological diseases, and immune system diseases. At the end of this review, we focus on the effect of cholesterol metabolism on eye diseases. In short, we hope to provide more new ideas for the pathogenesis and treatment of diseases from the perspective of cholesterol.

show abstract

Atherosclerosis and cardiovascular disease in systemic lupus erythematosus: effects of in vivo statin treatment

Abstract: Our overall data suggest that fluvastatin improves the impairment of a redox-sensitive pathway involved in processes that collectively orchestrate the pathophysiology of atherothrombosis in SLE.

Cited by 51 publications

References 35 publications

Cardiovascular Events in Systemic Lupus Erythematosus: Mechanisms for the Accelerated Development of Atherosclerosis, Diagnosis, Correction Capabilities

Cardiovascular Events in Systemic Lupus Erythematosus: Mechanisms for the Accelerated Development of Atherosclerosis, Diagnosis, Correction Capabilities

Update on cardiovascular disease in lupus

Cholesterol metabolism: physiological regulation and diseases

Contact Info

Product

Resources

About